For the Culture By The Culture. ISSN: 3064-9331.
Legal cannabis has generated nearly $25 billion in tax revenue, with $4.4 billion collected in 2024 alone. States benefit significantly, funding various community programs. However, equity issues remain, as many who contributed to legalization are still marginalized. The promise of justice is overshadowed by bureaucracy and economic barriers for legacy growers.
Celebrity weed is everywhere, flashy, overpriced, and often full of mids. This piece rips the gloss off the jars and calls out the marketing machine hijacking cannabis culture. Real smokers know the difference between herb and hype. This is your wake-up call.
Legacy growers fought for legalization, only to be pushed aside by the system they helped create. This feature exposes how red tape, taxes, and policy failures are locking out the real pioneers while corporate weed cashes in. It’s not just exclusion—it’s cultural erasure. And if we’re not careful, the soul of cannabis will vanish under glossy branding and mediocre bud.
Colorado just lost $20 million in cannabis sales, and it’s not a fluke. From hemp loopholes to collapsing tourism, this feature investigates what’s really behind the budget cuts and how the cracks in Colorado’s cannabis economy could foreshadow a national unraveling. If the “gold standard” of legalization is struggling, what does that mean for everyone else?
Gold Flora’s implosion wasn’t a one-off—it was a warning. From ballooned budgets to influencer-backed ego trips, Big Weed’s collapse in California shows what happens when hype and hubris replace substance and sustainability. We break it all down and expose how the industry got too loud, too fast, and now can’t afford the silence.
The DEA is delaying the rescheduling of marijuana from Schedule I, despite overwhelming scientific support and recommendations from health authorities. This stalling harms the cannabis industry, patients, and communities affected by marijuana criminalization. Political influences from big pharmaceutical companies contribute to this resistance, prolonging the adverse effects of current drug policies.
